By addressing the underlying factor of obesity, GLP-1 agonists offer a novel and potentially transformative approach to managing sleep apnea and improving sleep quality, leading to better overall health and well-being
2025, Jul, 22;16(1):6411 Bruno RM, Badhwar S, Abid L, Agharazii M, Anastasio F, Bellien J, et al
Step 1: The Warm-up Begin with a warm-up dose of 0.25 mg once a week for the first four weeks
This triple mechanism does not treat a disease endpoint it reprograms the metabolic environment in which obesity, type 2 diabetes, MASH, cardiovascular disease, and multiple chronic conditions emerge and progress
8 B ) or overall speed ( p = 0.304, t (41) = 1.041, independent-sample t test, two-tailed
NEW YORK, Oct